Search Results 1-10 of 13165 for Mektovi

  1. Binimetinib (oral route) - Mayo Clinic

    Mektovi. Back to top. Description. Binimetinib is used in combination with encorafenib to treat melanoma (skin cancer) that has spread or cannot be removed by ...

  2. Drugs and Supplements that Start with M - Mayo Clinic

    Mektovi. Also known as. Binimetinib (oral route). Melfiat. Also known as. Phendimetrazine (oral route) · Meloxicam (intravenous route) · Meloxicam (oral route).

  3. Cancer News - Medical Professionals - Mayo Clinic

    Medical Professionals news and the latest information about Cancer.

  4. Cancer Treatment! Clinical Trials - Mayo Clinic Research

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 in ...

  5. Drugs and Supplements that Start with M - Mayo Clinic

    Mektovi. Also known as. Binimetinib (oral route). Melfiat. Also known as. Phendimetrazine (oral route) · Meloxicam (intravenous route) · Meloxicam (oral route).

  6. Plexiform neurofibroma - Diagnosis and treatment - Mayo Clinic

    Researchers are now studying whether other MEK inhibitors — such as trametinib (Mekinist) and binimetinib (Mektovi) — can provide similar or better tumor ...

  7. Vulvar cancer - Doctors and departments - Mayo Clinic

    Learn about this rare cancer that forms on the skin that surrounds the urethra and vagina. Treatments include surgery, radiation and chemotherapy.

  8. Biological Therapy For Cancer Clinical Trials - Mayo Clinic Research

    This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

  9. Endometrial cancer - Doctors and departments - Mayo Clinic

    Learn about the symptoms and causes of this cancer of the uterus. Treatments include hysterectomy, radiation therapy, and chemotherapy and other medicines.

  10. Making up for lost time in GI cancers - Mayo Clinic

    ... (Mektovi) compared with cetuximab plus irinotecan-containing regimens.8. Data presented at the 2020 American Society of Clinical Oncology Virtual Scientific ...